A new programme unveiled by Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and the European Foundation for the Study of Diabetes (EFSD) has invited European diabetes research projects to send in their applications
A mist inhaler used to improve breathing in people with lung diseases including chronic bronchitis and emphysema may increase their risk of dying by 52 per cent, US and British researchers said.
The increased risk occurred in patients who
Phase III studies of Linagliptin, a compound being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes, showed that the drug significantly lowered blood glucose, a report said.
The drug, a dipeptidyl pept
A pink sex pill offered little help to women and came with unacceptable risks, US government advisers agreed on Friday, another setback in the search for a drug to boost female libido.
German drugmaker Boehringer Ingelheim failed to convin
Patients at risk of stroke due to an erratic heartbeat should soon have a viable alternative to 50-year-old warfarin, after a new pill from Boehringer Ingelheim beat expectations in a major clinical study.
The strong showing for the unlist